Loading
NASDAQHealthcareBiotechnology
Latest quote
$18.21
+$0.71 · +4.06%
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Previous close
$18.21
+$0.71 · +4.06%
After-hours
$18.3196
+$0.1096 · +0.60%
Oct 8, 7:42 PM ET
Regular session · ET · Market data may be delayed.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Day range
Current $18.21
52-week range
Current $18.21
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
80
Undervalued
Sentiment
71
Bullish
Risk
45
Elevated Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Day range
Current $18.21
52-week range
Current $18.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.2B USD | 1.9B USD | 1.24B USD | 933.01M USD | 701.89M USD |
| Cost of goods sold | 881.5M USD | 319.1M USD | 150.34M USD | 139.99M USD | 97.05M USD |
| Gross profit | 1.32B USD | 1.58B USD | 1.09B USD | 793.02M USD | 604.84M USD |
| Research and development | 1.52B USD | 804.52M USD | 877.39M USD | 877.09M USD | 771.18M USD |
| Selling, general, and administrative | 478.94M USD | 557.87M USD | 481.87M USD | 451.42M USD | 282.66M USD |
| Operating expenses | 1.97B USD | 1.36B USD | 1.36B USD | 1.33B USD | 1.06B USD |
| Interest income | 19.57M USD | 71.77M USD | 85.97M USD | 27.72M USD | 511K USD |
| Interest expense | 9.73M USD | 18.39M USD | 22.01M USD | 53.25M USD | 63.53M USD |
| Depreciation and amortization | 44.52M USD | 37.72M USD | 44.4M USD | 41.86M USD | 38.02M USD |
| Operating income | −657.77M USD | 218.08M USD | −267.82M USD | −536.2M USD | −459.71M USD |
| Net income | −713.41M USD | 235.24M USD | −535.98M USD | −703.49M USD | −418.78M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
